01 November, 2020, Melbourne, Victoria - Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly...

June 4, 2019, Melbourne, Victoria –Trial results demonstrate excellent PVX108 safety profile in patients with prior anaphylaxis and...

May 28, 2019, Melbourne, Victoria – Data show that PVX108 demonstrates exceptional safety in adults with peanut allergy Aravax, a...

February 25, 2019, Melbourne, Australia – Melbourne biotech to take its revolutionary peanut allergy treatment to Phase II clinical...

February 13, 2019, MELBOURNE, Australia – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly...

2 May 2018, Melbourne, Victoria – Aravax has received an additional investment of $1.9M from the Australian Medical Research...